ID

38801

Description

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT01947855

Lien

https://clinicaltrials.gov/show/NCT01947855

Mots-clés

Versions (1)
  1. 05/11/2019 05/11/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

5 novembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes Mellitus, Type 2 NCT01947855

Anglais

Eligibility Diabetes Mellitus, Type 2 NCT01947855

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of type 2 diabetes mellitus prior to informed consent
Description

Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:
Description

Gender | Diet therapy | Exercise

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0012159
UMLS CUI [3]
C0015259
drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
Description

Pharmaceutical Preparations Absent | Antidiabetics Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0332197
pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)
Description

Pretreatment | Antidiabetics Oral Quantity | Exception Sulfonylurea | Exception Thiazolidinediones | Diabetes Therapy unchanged

Type de données

boolean

Alias
UMLS CUI [1]
C3539076
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C1265611
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0038766
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1257987
UMLS CUI [5,1]
C3274787
UMLS CUI [5,2]
C0442739
glycosylated haemoglobin (hba1c) at visit 1 (screening)
Description

HbA1c

Type de données

boolean

Alias
UMLS CUI [1]
C0019018
for patients without antidiabetic therapy : hba1c >=7.0 to =<10.0%
Description

Diabetes Therapy Absent | Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C3274787
UMLS CUI [1,2]
C0332197
UMLS CUI [2]
C0474680
for patients with one oral antidiabetic drug : hba1c >=7.0 to =<9.5%
Description

Antidiabetics Oral Quantity | Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0474680
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/l)
Description

Hyperglycemia Uncontrolled | Glucose level

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020456
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0428548
impaired renal function, defined as estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (mdrd) formula)
Description

Renal Insufficiency | Estimated Glomerular Filtration Rate | Renal Insufficiency Moderate MDRD formula | Renal Insufficiency Severe MDRD formula

Type de données

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C3811844
UMLS CUI [3,1]
C1565489
UMLS CUI [3,2]
C0205081
UMLS CUI [3,3]
C3839656
UMLS CUI [4,1]
C1565489
UMLS CUI [4,2]
C0205082
UMLS CUI [4,3]
C3839656
acute coronary syndrome, stroke or transient ischemic attack (tia) within 12 weeks prior to informed consent
Description

Acute Coronary Syndrome | Cerebrovascular accident | Transient Ischemic Attack

Type de données

boolean

Alias
UMLS CUI [1]
C0948089
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0007787
indication of liver disease, defined by serum levels of either alanine transaminase (alt), aspartate transaminase (ast), or alkaline phosphatase (alp) above 3 x upper limit of normal (uln)
Description

Indication Liver disease | Alanine aminotransferase increased | Aspartate aminotransferase increased | Serum alkaline phosphatase raised

Type de données

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0023895
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
UMLS CUI [4]
C1314665
Retour au début de la page

Similar models

Eligibility Diabetes Mellitus, Type 2 NCT01947855

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosis of type 2 diabetes mellitus prior to informed consent
boolean
C0011860 (UMLS CUI [1])
Gender | Diet therapy | Exercise
Item
male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:
boolean
C0079399 (UMLS CUI [1])
C0012159 (UMLS CUI [2])
C0015259 (UMLS CUI [3])
Pharmaceutical Preparations Absent | Antidiabetics Absent
Item
drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,
boolean
C0013227 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0935929 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Pretreatment | Antidiabetics Oral Quantity | Exception Sulfonylurea | Exception Thiazolidinediones | Diabetes Therapy unchanged
Item
pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)
boolean
C3539076 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0038766 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1257987 (UMLS CUI [4,2])
C3274787 (UMLS CUI [5,1])
C0442739 (UMLS CUI [5,2])
HbA1c
Item
glycosylated haemoglobin (hba1c) at visit 1 (screening)
boolean
C0019018 (UMLS CUI [1])
Diabetes Therapy Absent | Hemoglobin A1c measurement
Item
for patients without antidiabetic therapy : hba1c >=7.0 to =<10.0%
boolean
C3274787 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0474680 (UMLS CUI [2])
Antidiabetics Oral Quantity | Hemoglobin A1c measurement
Item
for patients with one oral antidiabetic drug : hba1c >=7.0 to =<9.5%
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0474680 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Hyperglycemia Uncontrolled | Glucose level
Item
uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/l)
boolean
C0020456 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0428548 (UMLS CUI [2])
Renal Insufficiency | Estimated Glomerular Filtration Rate | Renal Insufficiency Moderate MDRD formula | Renal Insufficiency Severe MDRD formula
Item
impaired renal function, defined as estimated glomerular filtration rate (egfr) <60 ml/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (mdrd) formula)
boolean
C1565489 (UMLS CUI [1])
C3811844 (UMLS CUI [2])
C1565489 (UMLS CUI [3,1])
C0205081 (UMLS CUI [3,2])
C3839656 (UMLS CUI [3,3])
C1565489 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C3839656 (UMLS CUI [4,3])
Acute Coronary Syndrome | Cerebrovascular accident | Transient Ischemic Attack
Item
acute coronary syndrome, stroke or transient ischemic attack (tia) within 12 weeks prior to informed consent
boolean
C0948089 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0007787 (UMLS CUI [3])
Indication Liver disease | Alanine aminotransferase increased | Aspartate aminotransferase increased | Serum alkaline phosphatase raised
Item
indication of liver disease, defined by serum levels of either alanine transaminase (alt), aspartate transaminase (ast), or alkaline phosphatase (alp) above 3 x upper limit of normal (uln)
boolean
C3146298 (UMLS CUI [1,1])
C0023895 (UMLS CUI [1,2])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C1314665 (UMLS CUI [4])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial